E
Ella Sorani
Publications - 10
Citations - 302
Ella Sorani is an academic researcher. The author has contributed to research in topics: Internal medicine & CXCR4. The author has an hindex of 4, co-authored 7 publications receiving 119 citations.
Papers
More filters
Journal ArticleDOI
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial
Bruno Bockorny,Bruno Bockorny,Valerya Semenisty,Teresa Macarulla,Erkut Borazanci,Brian M. Wolpin,Salomon M. Stemmer,Salomon M. Stemmer,Talia Golan,Talia Golan,Ravit Geva,Ravit Geva,Mitesh J. Borad,Katrina S. Pedersen,Joon Oh Park,Robert A. Ramirez,David Gutierrez Abad,Jaime Feliu,Andrés Muñoz,Mariano Ponz-Sarvise,Amnon Peled,Tzipora M. Lustig,Osnat Bohana-Kashtan,Stephen M. Shaw,Ella Sorani,Marya F. Chaney,Shaul Kadosh,Abi Vainstein Haras,Daniel D. Von Hoff,Manuel Hidalgo,Manuel Hidalgo +30 more
TL;DR: Results from the phase IIa COMBAT trial combining CXCR4 and PD-1 inhibition in patients with metastatic cancer show encouraging clinical responses in association with enhanced antitumor immune activation.
Journal ArticleDOI
Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial
Bruno Bockorny,Bruno Bockorny,Teresa Macarulla,Valerya Semenisty,Erkut Borazanci,Jaime Feliu,Mariano Ponz-Sarvise,David Gutierrez Abad,Paul E. Oberstein,Angela Tatiana Alistar,Andrés Muñoz,Ravit Geva,Carmen Guillén-Ponce,Mercedes Salgado Fernandez,Amnon Peled,Marya F. Chaney,Irit Gliko-Kabir,Liron Shemesh-Darvish,Debby Ickowicz,Ella Sorani,Shaul Kadosh,Abi Vainstein-Haras,Manuel Hidalgo +22 more
TL;DR: In this article, the authors evaluated the safety and efficacy of motixafortide and pembrolizumab combined to chemotherapy in patients with de novo metastatic PDAC and disease progression on front-line gemcitabine-based therapy.
Journal ArticleDOI
A Multi-Center Phase IIA Trial to Assess the Safety and Efficacy of BL-8040 (a CXCR4 Inhibitor) in Combination with Pembrolizumab and Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma (PDAC)
Manuel Hidalgo,Valerya Semenisty,Bruno Bockorny,Erkut Borazanci,D. D. Von Hoff,Jaime Feliu,M. Ponz Sarvise,D. Gutierrez Abad,Amnon Peled,Osnat Bohana-Kashtan,Y. Gozlan,Ella Sorani,Marya F. Chaney,Shaul Kadosh,A.V. Vainstein,Teresa Macarulla +15 more
TL;DR: Preliminary data from the ongoing COMBAT study Cohort 2 with the triple combination of BL-8040, Pembrolizumab and chemo, show promising ORR and DC results, and Notably all patients with PR and SD had an initial increase in CA 19-9 followed by a decrease.
Journal ArticleDOI
CXCR4 antagonist (BL-8040) to enhance antitumor effects by increasing tumor infiltration of antigen-specific effector T-cells.
Pankaj Gaur,Vivek Verma,Seema Gupta,Ella Sorani,Abi Vainstein Haras,Galia Oberkovitz,Amnon Peled,Samir N. Khleif +7 more
TL;DR: It is hypothesized that CXCR4 antagonism will result in movement of immune progenitor cells from BM to periphery leading to increased availability of T-cells in the periphery and better infiltration of effector cells into the TME.
Journal ArticleDOI
A phase IIa trial to assess the safety and efficacy of BL-8040 and pembrolizumab in patients with metastatic pancreatic adenocarcinoma (PDAC)
Manuel Hidalgo,Ron Epelbaum,Brian M. Wolpin,Salomon M. Stemmer,Ravit Geva,Talia Golan,Erkut Borazanci,Mitesh J. Borad,Katrina S. Pedersen,J.O. Park,Robert A. Ramirez,Amnon Peled,Tzipora M. Lustig,O. Bohana Kashtan,O. Rosenfeld,Ella Sorani,Katia Schlienger,A. Vainstein Haras,D. D. Von Hoff +18 more